pilsicainide has been researched along with Arrhythmia in 21 studies
pilsicainide: structure given in first source
pilsicainide : A secondary carboxamide resulting from the formal condensation of the amino group of 2,6-dimethylaniline with the carboxy group of (tetrahydro-1H-pyrrolizin-7a(5H)-yl)acetic acid. It is a sodium channel blocker which is used as an antiarrhythmic drug for the management of atrial tachyarrhythmias in Japan.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Population pharmacokinetics (PK) of a sodium channel-blocking antiarrhythmic, pilsicainide, was studied using the nonlinear mixed-effects modeling technique in 91 patients with cardiac arrhythmias (80 suspected Brugada syndrome [BrS] and 11 with atrial fibrillation) who received an intravenous infusion of 10 mg of the drug." | 9.12 | Population pharmacokinetic and pharmacodynamic analysis of a class IC antiarrhythmic, pilsicainide, in patients with cardiac arrhythmias. ( Echizen, H; Kishi, R; Kobayashi, S; Masuhara, K; Matsumoto, N; Mihara, K; Miyake, F; Nakazawa, K; Ogawa, R; Takagi, A; Takahashi, H, 2006) |
| "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d)." | 9.12 | Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. ( Fujimura, A; Ioka, T; Ookami, H; Sakamoto, K; Tsuruoka, S; Wakaumi, M, 2006) |
| "Pilsicainide induced VA in some patients with Brugada syndrome, but this result may not be used as a parameter of the risk stratification of Brugada syndrome." | 7.74 | Incidence and initial characteristics of pilsicainide-induced ventricular arrhythmias in patients with Brugada syndrome. ( Aizawa, Y; Chinushi, M; Furushima, H; Izumi, D; Komura, S; Tanabe, Y; Washizuka, T, 2007) |
| "A single oral dose of pilsicainide, a class 1c antiarrhythmic drug, is effective in terminating acute-onset atrial fibrillation (AF), but its effect on pacing thresholds in pacemaker patients is unknown." | 7.70 | Effect of a single oral dose of pilsicainide on pacing thresholds in pacemaker patients with and without paroxysmal atrial fibrillation. ( Abe, H; Kohshi, K; Nagatomo, T; Nakashima, Y; Numata, T, 2000) |
| "Antiarrhythmic effects of three new drugs, propafenone, tocainide, and SUN 1165, were examined using three canine ventricular arrhythmia models, i." | 7.67 | Canine digitalis arrhythmia as a model for detecting Na-channel blocking antiarrhythmic drugs: a comparative study using other canine arrhythmia models and the new antiarrhythmic drugs, propafenone, tocainide, and SUN 1165. ( Hashimoto, K; Ishii, M; Komori, S; Mitsuhashi, H, 1985) |
| " For this purpose, we plotted a dose-response curve for adrenaline by calculating the arrhythmic ratio, which is the number of ventricular ectopic beats induced by adrenaline divided by the total heart rate, and observed the changes in the arrhythmic ratio-adrenaline dose relation before and after administration of class I drugs." | 5.31 | QT-prolonging class I drug, disopyramide, does not aggravate but suppresses adrenaline-induced arrhythmias. Comparison with cibenzoline and pilsicainide. ( Aye, NN; Hashimoto, K; Miyamoto, S; Teramatsu, T; Zhu, B, 2000) |
| "Population pharmacokinetics (PK) of a sodium channel-blocking antiarrhythmic, pilsicainide, was studied using the nonlinear mixed-effects modeling technique in 91 patients with cardiac arrhythmias (80 suspected Brugada syndrome [BrS] and 11 with atrial fibrillation) who received an intravenous infusion of 10 mg of the drug." | 5.12 | Population pharmacokinetic and pharmacodynamic analysis of a class IC antiarrhythmic, pilsicainide, in patients with cardiac arrhythmias. ( Echizen, H; Kishi, R; Kobayashi, S; Masuhara, K; Matsumoto, N; Mihara, K; Miyake, F; Nakazawa, K; Ogawa, R; Takagi, A; Takahashi, H, 2006) |
| "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d)." | 5.12 | Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. ( Fujimura, A; Ioka, T; Ookami, H; Sakamoto, K; Tsuruoka, S; Wakaumi, M, 2006) |
| "Pilsicainide induced VA in some patients with Brugada syndrome, but this result may not be used as a parameter of the risk stratification of Brugada syndrome." | 3.74 | Incidence and initial characteristics of pilsicainide-induced ventricular arrhythmias in patients with Brugada syndrome. ( Aizawa, Y; Chinushi, M; Furushima, H; Izumi, D; Komura, S; Tanabe, Y; Washizuka, T, 2007) |
| "We administered pilsicainide chloride, a class Ic pure sodium channel blocker, to patients with Brugada syndrome (BS) and evaluated the occurrence of ventricular arrhythmia (VA) and T-wave alternans (TWA)." | 3.72 | Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome. ( Banba, K; Emori, T; Hina, K; Kita, T; Kusano, KF; Matsubara, H; Morita, H; Morita, ST; Nagase, S; Nakamura, K; Nishii, N; Ohe, T; Tani, Y; Watanabe, A, 2003) |
| " Pilsicainide (four patients) or flecainide (one patient) were administered orally for the treatment of symptomatic paroxysmal atrial fibrillation or premature atrial contractions." | 3.71 | ST segment elevation in the right precordial leads following administration of class Ic antiarrhythmic drugs. ( Kawano, Y; Mineda, Y; Nakata, Y; Nakazato, K; Nakazato, Y; Sekita, G; Sumiyoshi, M; Tokano, T; Yamashita, H; Yasuda, M, 2001) |
| " During hospitalization, atrial fibrillation developed, and oral pilsicainide was administered." | 3.71 | Class I antiarrhythmic drug and coronary vasospasm-induced T wave alternans and ventricular tachyarrhythmia in a patient with Brugada syndrome and vasospastic angina. ( Aizawa, Y; Chinushi, M; Chinushi, Y; Toida, T, 2002) |
| "Antiarrhythmic effects and cardiovascular effects of pilsicainide hydrochloride were compared with those of disopyramide in a canine model of coronary ligation-induced ventricular arrhythmias and anesthetized dogs." | 3.70 | [Antiarrhythmic effects of pilsicainide hydrochloride and effects on cardiac function and ECG in dogs: comparison with disopyramide]. ( Hayashi, Y; Hidaka, T; Inomata, N; Inoue, T; Komoriya, K, 2000) |
| "A single oral dose of pilsicainide, a class 1c antiarrhythmic drug, is effective in terminating acute-onset atrial fibrillation (AF), but its effect on pacing thresholds in pacemaker patients is unknown." | 3.70 | Effect of a single oral dose of pilsicainide on pacing thresholds in pacemaker patients with and without paroxysmal atrial fibrillation. ( Abe, H; Kohshi, K; Nagatomo, T; Nakashima, Y; Numata, T, 2000) |
| "The aim of this study was to elucidate whether the electrophysiologic properties of pilsicainide, a novel class IC drug with slow kinetic properties, could be altered in the presence of acute myocardial ischemia." | 3.69 | Ischemia enhances use-dependent sodium channel blockade by pilsicainide, a class IC antiarrhythmic agent. ( Ogawa, S; Sadanaga, T, 1994) |
| "Effects of SUN-1165, a class I antiarrhythmic drug, on ventricular arrhythmias, intraventricular conduction, and the effective refractory period (ERP) were examined in a canine model of myocardial infarction and compared with those of lidocaine." | 3.68 | Effects of SUN-1165, N-(2,6-dimethylphenyl)-8-pyrrolizidine acetamide hydrochloride hemihydrate, a new class I antiarrhythmic drug, on ventricular arrhythmias, intraventricular conduction, and the refractory period in canine myocardial infarction. ( Hashimoto, H; Nakashima, M; Satoh, N, 1992) |
| "Antiarrhythmic effects of three new drugs, propafenone, tocainide, and SUN 1165, were examined using three canine ventricular arrhythmia models, i." | 3.67 | Canine digitalis arrhythmia as a model for detecting Na-channel blocking antiarrhythmic drugs: a comparative study using other canine arrhythmia models and the new antiarrhythmic drugs, propafenone, tocainide, and SUN 1165. ( Hashimoto, K; Ishii, M; Komori, S; Mitsuhashi, H, 1985) |
| "The elderly patients are susceptible to acute renal failure due to dehydration or infection." | 1.36 | [Two elderly case reports of renal excretion type drug poisoning caused by dehydration that was due to poor eating in home care]. ( Doi, S; Hata, A; Hinokiyama, H; Ibata, T; Iijima, H; Komuro, R; Mito, S; Nakashita, C; Sato, M; Shiki, S, 2010) |
| " For this purpose, we plotted a dose-response curve for adrenaline by calculating the arrhythmic ratio, which is the number of ventricular ectopic beats induced by adrenaline divided by the total heart rate, and observed the changes in the arrhythmic ratio-adrenaline dose relation before and after administration of class I drugs." | 1.31 | QT-prolonging class I drug, disopyramide, does not aggravate but suppresses adrenaline-induced arrhythmias. Comparison with cibenzoline and pilsicainide. ( Aye, NN; Hashimoto, K; Miyamoto, S; Teramatsu, T; Zhu, B, 2000) |
| "Appropriate dosing of pilsicainide hydrochloride, an anti-arrhythmic drug excreted via the kidney, was investigated in patients on dialysis." | 1.31 | Appropriate dosing of pilsicainide hydrochloride in patients on hemodialysis. ( Fujii, Z; Fujimoto, K; Kawata, Y; Matsumoto, M; Matsuzaki, M; Minami, M; Nawata, C; Sakumura, T, 2001) |
| "In conscious dogs without arrhythmia, SUN 1165 had no deleterious cardiohemodynamic effect and no gross behavioral effect at the oral doses of 3 and 10 mg/kg." | 1.27 | N-(2,6-Dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate (SUN 1165): a new potent and long-acting antiarrhythmic agent. ( Aisaka, K; Hamasaki, S; Hidaka, T; Inomata, N; Ishihara, T; Morita, M, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 4 (19.05) | 18.2507 |
| 2000's | 14 (66.67) | 29.6817 |
| 2010's | 1 (4.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ibata, T | 1 |
| Hinokiyama, H | 1 |
| Nakashita, C | 1 |
| Mito, S | 1 |
| Doi, S | 1 |
| Shiki, S | 1 |
| Hata, A | 1 |
| Sato, M | 1 |
| Komuro, R | 1 |
| Iijima, H | 1 |
| Morita, H | 1 |
| Morita, ST | 1 |
| Nagase, S | 1 |
| Banba, K | 1 |
| Nishii, N | 1 |
| Tani, Y | 1 |
| Watanabe, A | 1 |
| Nakamura, K | 1 |
| Kusano, KF | 1 |
| Emori, T | 1 |
| Matsubara, H | 1 |
| Hina, K | 1 |
| Kita, T | 1 |
| Ohe, T | 1 |
| Wakaumi, M | 2 |
| Tsuruoka, S | 2 |
| Sakamoto, K | 2 |
| Shiga, T | 1 |
| Fujimura, A | 2 |
| Yamakawa, M | 1 |
| Sunagawa, M | 1 |
| Shimabukuro, M | 1 |
| Higa, N | 1 |
| Takasu, N | 1 |
| Kosugi, T | 1 |
| Ogawa, R | 1 |
| Kishi, R | 2 |
| Mihara, K | 1 |
| Takahashi, H | 1 |
| Takagi, A | 2 |
| Matsumoto, N | 1 |
| Masuhara, K | 1 |
| Nakazawa, K | 2 |
| Miyake, F | 2 |
| Kobayashi, S | 1 |
| Echizen, H | 1 |
| Ioka, T | 1 |
| Ookami, H | 1 |
| Whomsley, R | 1 |
| Strolin-Benedetti, M | 1 |
| Baltes, E | 1 |
| Sakurai, T | 1 |
| Osada, K | 1 |
| Ryu, S | 1 |
| Fujita, S | 1 |
| Matsuda, H | 1 |
| Ishikawa, Y | 1 |
| Chinushi, M | 2 |
| Komura, S | 1 |
| Izumi, D | 1 |
| Furushima, H | 1 |
| Tanabe, Y | 1 |
| Washizuka, T | 1 |
| Aizawa, Y | 2 |
| Sadanaga, T | 3 |
| Ogawa, S | 3 |
| Okada, Y | 2 |
| Tsutsumi, N | 1 |
| Iwanaga, S | 1 |
| Yoshikawa, T | 1 |
| Akaishi, M | 1 |
| Handa, S | 2 |
| Hidaka, T | 2 |
| Inoue, T | 1 |
| Komoriya, K | 1 |
| Hayashi, Y | 1 |
| Inomata, N | 2 |
| Miyamoto, S | 1 |
| Zhu, B | 1 |
| Teramatsu, T | 1 |
| Aye, NN | 1 |
| Hashimoto, K | 2 |
| Numata, T | 1 |
| Abe, H | 1 |
| Nagatomo, T | 1 |
| Kohshi, K | 1 |
| Nakashima, Y | 1 |
| Yasuda, M | 1 |
| Nakazato, Y | 1 |
| Yamashita, H | 1 |
| Sekita, G | 1 |
| Kawano, Y | 1 |
| Mineda, Y | 1 |
| Nakazato, K | 1 |
| Tokano, T | 1 |
| Sumiyoshi, M | 1 |
| Nakata, Y | 1 |
| Matsumoto, M | 1 |
| Fujii, Z | 1 |
| Kawata, Y | 1 |
| Sakumura, T | 1 |
| Minami, M | 1 |
| Fujimoto, K | 1 |
| Nawata, C | 1 |
| Matsuzaki, M | 1 |
| Chinushi, Y | 1 |
| Toida, T | 1 |
| Hashimoto, H | 1 |
| Satoh, N | 1 |
| Nakashima, M | 1 |
| Ishii, M | 1 |
| Komori, S | 1 |
| Mitsuhashi, H | 1 |
| Aisaka, K | 1 |
| Hamasaki, S | 1 |
| Ishihara, T | 1 |
| Morita, M | 1 |
3 trials available for pilsicainide and Arrhythmia
| Article | Year |
|---|---|
Population pharmacokinetic and pharmacodynamic analysis of a class IC antiarrhythmic, pilsicainide, in patients with cardiac arrhythmias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Bundle-Branch Block; | 2006 |
Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.
Topics: Administration, Oral; Adult; Aged; Animals; Anti-Arrhythmia Agents; Area Under Curve; Arrhythmias, C | 2006 |
Discrimination of Brugada syndrome patients from individuals with the saddle-back type ST-segment elevation using a marker of the standard 12-lead electrocardiography.
Topics: Adult; Aged; Arrhythmias, Cardiac; Biomarkers; Brugada Syndrome; Diagnosis, Differential; Electrocar | 2007 |
18 other studies available for pilsicainide and Arrhythmia
| Article | Year |
|---|---|
[Two elderly case reports of renal excretion type drug poisoning caused by dehydration that was due to poor eating in home care].
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dehydrat | 2010 |
Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bundle-Branch Block; Electrocardiography; Femal | 2003 |
Pilsicainide in breast milk from a mother: comparison with disopyramide and propafenone.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Breast Feeding; Disopyramide; Female; Humans; Lidocain | 2005 |
Effect of sodium channel blocker, pilsicainide hydrochloride, on net inward current of atrial myocytes in thyroid hormone toxicosis rats.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Electrocardiography; Heart Atria; Lidocaine; Male; | 2005 |
Comment on severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency.
Topics: Aged; Area Under Curve; Arrhythmias, Cardiac; Cetirizine; Drug Interactions; Female; Half-Life; Huma | 2006 |
Incidence and initial characteristics of pilsicainide-induced ventricular arrhythmias in patients with Brugada syndrome.
Topics: Adult; Aged; Arrhythmias, Cardiac; Brugada Syndrome; Electrocardiography; Electrophysiologic Techniq | 2007 |
Ischemia enhances use-dependent sodium channel blockade by pilsicainide, a class IC antiarrhythmic agent.
Topics: Acute Disease; Aged; Analysis of Variance; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chi-Square | 1994 |
Clinical evaluation of the use-dependent QRS prolongation and the reverse use-dependent QT prolongation of class I and class III antiarrhythmic agents and their value in predicting efficacy.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Drug Evaluation; Electrocar | 1993 |
[Antiarrhythmic effects of pilsicainide hydrochloride and effects on cardiac function and ECG in dogs: comparison with disopyramide].
Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Vessels; Disease Models, | 2000 |
QT-prolonging class I drug, disopyramide, does not aggravate but suppresses adrenaline-induced arrhythmias. Comparison with cibenzoline and pilsicainide.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Disopyramide; Dogs; Drug Inte | 2000 |
Effect of a single oral dose of pilsicainide on pacing thresholds in pacemaker patients with and without paroxysmal atrial fibrillation.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardi | 2000 |
ST segment elevation in the right precordial leads following administration of class Ic antiarrhythmic drugs.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Electrocardiography; Female | 2001 |
Appropriate dosing of pilsicainide hydrochloride in patients on hemodialysis.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Premature Complexes; Echocardiography; Electroc | 2001 |
Class I antiarrhythmic drug and coronary vasospasm-induced T wave alternans and ventricular tachyarrhythmia in a patient with Brugada syndrome and vasospastic angina.
Topics: Acetylcholine; Angina Pectoris, Variant; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 2002 |
[Clinical significance of the use-dependent sodium channel block and reverse use-dependent potassium channel block of class I and class III antiarrhythmic agents and their values to predict drug efficacy].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Drug Evaluation; Electrocardiography, Am | 1992 |
Effects of SUN-1165, N-(2,6-dimethylphenyl)-8-pyrrolizidine acetamide hydrochloride hemihydrate, a new class I antiarrhythmic drug, on ventricular arrhythmias, intraventricular conduction, and the refractory period in canine myocardial infarction.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Dogs; Electric Stimul | 1992 |
Canine digitalis arrhythmia as a model for detecting Na-channel blocking antiarrhythmic drugs: a comparative study using other canine arrhythmia models and the new antiarrhythmic drugs, propafenone, tocainide, and SUN 1165.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Vessels; Dogs; Epinephrine; Female; | 1985 |
N-(2,6-Dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate (SUN 1165): a new potent and long-acting antiarrhythmic agent.
Topics: Anesthetics, Local; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cell Membrane; Coronary C | 1985 |